Pulse Biosciences (NASDAQ:PLSE) Earns Buy Rating from Analysts at Needham & Company LLC

Needham & Company LLC initiated coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a report issued on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $58.00 price target on the stock.

PLSE has been the topic of a number of other research reports. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Mizuho set a $45.00 target price on Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group raised their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pulse Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Stock Up 2.2%

PLSE opened at $47.02 on Monday. The stock has a market cap of $3.25 billion, a P/E ratio of -39.85 and a beta of 1.61. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $48.84. The company has a fifty day simple moving average of $32.14 and a 200 day simple moving average of $25.43.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. On average, equities research analysts expect that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Formula Growth Ltd. bought a new position in shares of Pulse Biosciences during the second quarter worth about $832,000. Panoramic Capital LLC acquired a new stake in Pulse Biosciences in the 2nd quarter valued at approximately $2,719,000. Bank of America Corp DE bought a new stake in Pulse Biosciences in the 2nd quarter valued at approximately $40,115,000. Jupiter Topco LLC bought a new stake in Pulse Biosciences in the 2nd quarter valued at approximately $241,000. Finally, Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter worth approximately $28,000. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.